Sanofi (NASDAQ:SNY) Shares Sold by Integrated Investment Consultants LLC

Integrated Investment Consultants LLC reduced its position in Sanofi (NASDAQ:SNY) by 10.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,855 shares of the company’s stock after selling 550 shares during the quarter. Integrated Investment Consultants LLC’s holdings in Sanofi were worth $280,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of SNY. Boston Partners increased its position in Sanofi by 0.3% in the 1st quarter. Boston Partners now owns 13,066,403 shares of the company’s stock valued at $635,280,000 after acquiring an additional 33,657 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Sanofi by 19.0% during the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock worth $417,017,000 after purchasing an additional 1,370,232 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC lifted its holdings in shares of Sanofi by 113.8% during the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after purchasing an additional 3,164,092 shares during the period. Envestnet Asset Management Inc. grew its position in Sanofi by 8.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock valued at $157,803,000 after buying an additional 246,224 shares during the last quarter. Finally, Federated Hermes Inc. increased its stake in Sanofi by 26.5% in the 2nd quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock valued at $155,950,000 after buying an additional 673,172 shares during the period. 10.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

SNY has been the topic of several analyst reports. Argus lifted their target price on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Finally, Citigroup upgraded Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Stock Up 0.6 %

SNY stock opened at $48.28 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The company’s 50-day moving average price is $53.70 and its 200 day moving average price is $52.15. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97. The company has a market cap of $122.53 billion, a P/E ratio of 24.63, a P/E/G ratio of 1.22 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same quarter in the previous year, the company earned $2.55 EPS. The company’s quarterly revenue was up 12.3% on a year-over-year basis. On average, research analysts expect that Sanofi will post 4.29 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.